HC Wainwright Has Pessimistic View of HRTX FY2026 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued to investors on Wednesday, June 3rd. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings of ($0.09) per share for the year, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for Heron Therapeutics’ FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.12 EPS, FY2029 earnings at $0.22 EPS and FY2030 earnings at $0.32 EPS.

Other analysts have also issued reports about the company. Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.50.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $0.48 on Friday. Heron Therapeutics has a one year low of $0.43 and a one year high of $2.30. The firm has a market capitalization of $91.52 million, a price-to-earnings ratio of -2.69 and a beta of 1.58. The business has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $1.11. The company has a debt-to-equity ratio of 17.51, a current ratio of 2.53 and a quick ratio of 1.51.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative net margin of 20.53% and a negative return on equity of 7,747.30%. The firm had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million.

Hedge Funds Weigh In On Heron Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HRTX. PKS Advisory Services LLC acquired a new position in Heron Therapeutics during the 3rd quarter valued at about $25,000. Advisory Services Network LLC boosted its stake in Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 18,114 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Heron Therapeutics during the 2nd quarter valued at about $26,000. R Squared Ltd acquired a new position in Heron Therapeutics during the 1st quarter valued at about $27,000. Finally, Jones Financial Companies Lllp boosted its stake in Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 23,661 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.